Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1999-01-28
2000-08-29
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
A61K 31135
Patent
active
061109738
ABSTRACT:
Methods are disclosed utilizing the optically pure (-)-isomer of bupropion, which is a potent drug for treating obesity and weight gain.
REFERENCES:
patent: Re33994 (1992-07-01), Baker et al.
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3622675 (1971-11-01), Koppe et al.
patent: 3630200 (1971-12-01), Higuchi
patent: 3819706 (1974-06-01), Mehta
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3885046 (1975-05-01), Mehta
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3960927 (1976-06-01), Metcalf et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4347176 (1982-08-01), Mehta
patent: 4347177 (1982-08-01), Phillips
patent: 4347178 (1982-08-01), Findlay et al.
patent: 4347257 (1982-08-01), Stern
patent: 4347382 (1982-08-01), Scharver
patent: 4355179 (1982-10-01), Findlay et al.
patent: 4356165 (1982-10-01), Findlay et al.
patent: 4393078 (1983-07-01), Peck
patent: 4425363 (1984-01-01), Stern
patent: 4435449 (1984-03-01), Stern
patent: 4438138 (1984-03-01), Stern
patent: 4507323 (1985-03-01), Stern
patent: 4571395 (1986-02-01), Peck
patent: 4656026 (1987-04-01), Coffman et al.
patent: 4687660 (1987-08-01), Baker et al.
patent: 4769027 (1988-09-01), Baker et al.
patent: 4798826 (1989-01-01), Peck
patent: 4835147 (1989-05-01), Roberts
patent: 4868344 (1989-09-01), Brown
patent: 4895845 (1990-01-01), Seed
patent: 4935429 (1990-06-01), Dackis et al.
patent: 4935439 (1990-06-01), Kashman et al.
patent: 5358970 (1994-10-01), Ruff et al.
patent: 5427798 (1995-06-01), Ludwig et al.
patent: 5447948 (1995-09-01), Seibyl et al.
patent: 5512593 (1996-04-01), Dante
patent: 5541231 (1996-07-01), Ruff et al.
patent: 5731000 (1998-03-01), Ruff et al.
patent: 5753712 (1998-05-01), Pinsker
patent: 5763493 (1998-06-01), Ruff et al.
Charney, D.S. et al., 1983, "Monoamine receptor sensitivity and depression: clinical studies of antidepressant effects on serotonin and noradrenergic function", Psychopharmacol. Bull. 19(3):490.
Ferry, L.H. et al., 1992, "Enhancement of smoking cessation using the anti-depressant bupropion hydrochloride" (abstract) Circulation 86:671.
Ferry, L.H. et al., 1994, "Efficacy of bupropion for smoking cessation in non-depressed smokers", J. Addict. Dis. 13:A9.
Goetz et al., 1984, "Bupropion in Parkinson's Disease" 34:1092-4.
Merskey, H., 1965, "The effect of chronic pain upon the response to noxious stimuli by psychiatric patients", J. Psychosom. Res. 8:405.
Nutt, D.J. et al., 1981, "Studies on the postietal rise in seizure threshold", Eur. J. Pharmacol. 71:287-295.
Nutt, D.J. et al., 1980, "On the measurement in rats of the convulsant effect of drugs and the changes which follow electroconvulsive shock", Neuropharmacology 19:1017-1023.
Sulser, F., 1983, "Molecular mechanisms in antidepressant action", Psychopharmacol. Bull. 19(3):300.
Ward, N.G., 1990, The Management of Pain, Second Edition, vol. I, Chapter 18, (eds.) Bonica, J.J. pp. 310-319.
Blondel-Hill et al., 1993, "Treatment of the chronic fatigue syndrome", Drugs 46(4):639-651.
Cooke C.E., 1997, "Therapeutic advances in the treatment of cigarette addiction", J. Pharmacy Practice 10(5):329-337.
Crenshaw et al., 1987, "Pharmacological modification of psychosexual dysfunction", J. Sex. Marital Ther. 13(4):239-252.
Garland et al., 1998, "Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats", J. Psychopharmacology 12(4):385-395.
Hsyu, P.H. et al., 1997, "Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers", J. Clin. Pharmacol. 37(8):737-743.
Hsyu, P.H. et al., Nov. 10, 1997 Chemical Abstracts 127(19): Abstract No. 257089; Columbus, Ohio.
McNamee et al., 1986, "Stimulation of substrate oxidation in rat hepatic mitochondria following pretreatment with appetite modifying drugs", J. Pharm. Pharmacol. 37:147.
Pearlstein et al., 1997, "Comparison of fluoxetine, bupropion, and placebo in the treatment of prementrual dysphoric disorder", J. Clin. Psychopharmacol. 17(4):261-266.
Wright et al., 1985, "Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects", J. Clin. Psych. 46(1):22-55.
Zarrindast et al., 1988, "Anorectic and behavioral effects of bupropion", Gen. Pharmacology 19(2):201-204.
Ascher, J.A. et al., 1995, "Bupropion: a review of its mechanism of antidepressant activity", J. Clin. Psych. 56:395-401.
Bannon et al., 1998, "Broad-spectrum, non-opoid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors", Science 279:77-81.
Bischoff et al., 1984, "Affinity changes of rat striatal dopamine receptor in vivo after acute bupropion treatment", Eur. J. Pharmaco. 104:173-176.
Borowski, T.B. et al., 1993, "Amphetamine and antidepressant drug effects on GABA- and NMDA-related seizures", Brain Res. Bull. 30:607-610.
Calabrese, J.R. et al., 1991, "Treatment of depression", Primary Care 18(2):421-433.
Castaldi, G. et al., 1987, Tartaric acid, an efficient chiral auxilliary: new asymmetric synthesis of 2-.
Clay et al., 1988, "Clinical and neuropsychological effects of the novel antidepressant bupropion", Psycopharma. Bull. 24(1):143-148.
Conners, K.C. et al., 1996, "Bupropion hydrochloride in attention deficit disorder with hyperactivity", J. Am. Acad. Child Adolesc. Psychiatr. 34(10):1314-1321.
Cooper, B.R. et al., 1994, "Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin.RTM.) are mediated by a noradrenergic mechanism", Neuropsychopharmacology 11(2):133-141.
Cooper, T.B. et al., "Analytical psychopharmacology", Analytical Psychopharmacology: NY State Psychiatric Institute pp. 1-3, 1994.
Coutts, R.T. & Baker, G.B., 1989, "Implications of chirality and geometric isomerisms in some psyhoactive drugand their metabolites", Chirality 1:99-120.
Cusack, B. et al., 1994, "Binding of antidepressants to human brain receptors: focus on newer generation compounds", Psychopharmacol. 114:559-565.
Davidson et al., 1994, "Bupropion in chronic low back pain", J. Clin. Psychiatry 55(8):362.
Dilsaver, S.C. et al., 1992, "The efficacy of bupropion in winter depression: results of an open trial", J. Clin. Psychiatry 53(7):252-255.
Eliel, E.L., 1962, Stereochemistry of Carbon Compounds, McGraw-Hill, NY.
Ferris, R.M. et al., 1983, "Studies of bupropion's mechanism of antidepressant activity", J. Clin. Psychiatry 44(5):74-78.
Ferris & Beaman, 1983, "Bupropion: a new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic .beta.-adrenergic, serotonergic (5-HT.sub.2), .alpha..sub.2 -adrenergic, imipramine and dopaminergic receptors in brain", Neuropharmacol. 22(1):1257-1267.
Fisher, R.S., 1989, "Animal models of the epilepsies", Brain Res. Reviews 14:245-278.
Foote et al., 1984, "Proconvulsant effect of morphine on seizures induced by pentylenetetrazol in the rat", 105:179-184.
Goodnick, P.J., 1994, "Pharmacokinetic optimisation of therapy with newer antidepressants", Clin. Pharmacokinet. 27(4):307-330.
Goodnick, P.J. & Sandoval, R., 1993, "Psychotropic treatment of depression: results of an open trial", J. Clin. Psych. 54(1):13-20.
Green, A.R. & Murray, T.K., 1989, "A simple intravenous infusion method in rodents for determining the potency of anticonvulsants acting through GABAergic mechanisms", J. Pharm. Pharmacol. 41:879-880.
Grimes et al., 1996, "Spontaneous orgasm with the combined use of bupropion and sertraline", Soc. Biol. Psych. 40:1184-1185.
Kelley, J.L. et al., 1996, "(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake", J. Med. Chem. 39:347-349.
Ketter, T.A. et al., 1995, "Carbamazepine but not valproate induces bupropion metabolism", J. Clin. Psycopharmacol. 15(5):327-333.
Laizure S.C. et al., 1985, Pharmacokinetics of bupropion and its major basic metabolites in normal.
Lief, H.I., 1996, "Bupropion treatment of depression to assist smoking cessation", Am. J. Psychiatry 153(3):442.
Little, K.Y. et al., 1993, "[.sup.125 I]RTI-55 binding to cocaine-sensitive
Jarvis William R. A.
Sepracor
LandOfFree
Methods for treating obesity and weight gain using optically pur does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating obesity and weight gain using optically pur, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating obesity and weight gain using optically pur will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1250487